Wegapan-DSR Capsule is a combination pharmaceutical formulation containing Domperidone 30 mg and Pantoprazole 40 mg, designed to provide effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and reducing symptoms such as nausea, vomiting, and bloating. Pantoprazole, a proton pump inhibitor, suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, providing relief from acid-related conditions such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers. The synergistic action of these two agents in Wegapan-DSR Capsule addresses both motility and acid secretion abnormalities, making it suitable for patients experiencing dyspepsia, acid reflux, and related gastrointestinal discomfort. This combination therapy improves patient compliance by reducing the pill burden and enhancing therapeutic efficacy. Wegapan-DSR should be administered as prescribed by a healthcare professional, with consideration of contraindications such as hypersensitivity to either component, and caution in patients with cardiac arrhythmias or hepatic impairment. Adverse effects may include headache, dry mouth, abdominal cramps, or diarrhea. Regular monitoring and adherence to dosing guidelines are recommended to ensure optimal clinical outcomes.